Welcome to our dedicated page for Sol Gel Tech news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Tech stock.
Sol-Gel Technologies Ltd. reports clinical, regulatory and commercial developments for a dermatology business focused on topical drug products for skin diseases. Company updates center on SGT-610, patidegib gel 2%, for the prevention of new basal cell carcinomas in Gorlin syndrome, and SGT-210, erlotinib ointment 5%, which has been evaluated in rare skin keratoderma indications including Darier disease.
News also covers TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea, including product approvals and territorial licensing or commercialization arrangements. Financial releases discuss research and development spending, revenue tied to partnerships and approved products, cash resources, shareholder voting matters, and capital-structure actions such as the company's reverse share split.
Sol-Gel (NASDAQ: SLGL) reported Q1 2026 revenue of $0.1 million, down from $1.0 million in Q1 2025, and a net loss of $3.7 million ($1.31 per share), versus a $8.8 million loss a year earlier.
Research and development expenses fell to $2.8 million from $8.8 million. Cash, deposits and marketable securities totaled $52.8 million as of March 31, 2026, which is expected to fund operations into Q1 2028.
Recent milestones include a Notice of Allowance for a method-of-use patent protecting SGT-610 until 2044, an oversubscribed $33.1 million underwritten offering, ongoing Phase 3 development of SGT-610 in Gorlin syndrome with top-line results anticipated in Q4 2026, and an exclusive TWYNEO® commercialization license in India with Sun Pharma plus broader global partnership expansion.
Sol-Gel Technologies (NASDAQ: SLGL) priced an underwritten offering of 459,112 ordinary shares at $72.00 per share, generating approximately $33.1 million in gross proceeds before fees. The offering is expected to close on or about March 25, 2026, subject to customary closing conditions.
The company said it intends to use net proceeds to fund continued development and pre-commercialization of SGT-610, plus R&D, working capital and general corporate purposes. Joint book-runners are TD Cowen and LifeSci Capital.
Sol-Gel (NASDAQ: SLGL) filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 on March 19, 2026, including audited 2025 financial statements.
The Form 20-F is available on the SEC website and the company investor relations site, and a free hard copy is available on request to the CFO.
Sol-Gel is a dermatology company developing SGT-610 (Phase 3, orphan- and breakthrough-designated) for Gorlin syndrome, advancing SGT-210, and commercializing FDA-approved products TWYNEO and EPSOLAY.
Sol-Gel (NASDAQ: SLGL) announced results after unblinding a vehicle-controlled Phase 1b proof-of-concept study of SGT-210 in Darier disease on Dec 17, 2025. The company reported that the study did not show differentiation between SGT-210 and vehicle on efficacy assessments, and will not advance SGT-210 to the next development stage in Darier disease. The company said it plans to pursue very small, low-cost feasibility studies of SGT-210 in other indications with stronger mechanistic rationale. Sol-Gel also reiterated its ongoing focus on completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparatory activities for a potential Phase 3 program in high-frequency BCC, contingent on Gorlin Phase 3 success.
Sol-Gel (NASDAQ: SLGL) reported Q3 2025 results and corporate updates on November 20, 2025. Total revenue was $0.4M versus $5.4M year-ago. R&D expenses were $5.7M; net loss was $5.9M or $2.13 per share. Cash, equivalents and marketable securities totaled $20.9M, with a cash runway into Q1 2027.
Pipeline and corporate highlights: Health Canada approved EPSOLAY; Sol-Gel signed an Australia/New Zealand license with Viatris; company expects EPSOLAY launches in 2027 and TWYNEO launches in 2028. Sol-Gel anticipates partner-driven royalties growing to ~$10M by 2031. The pivotal Phase 3 trial of SGT-610 (Gorlin) is ongoing with top-line results expected in Q4 2026; company plans to pursue high-frequency BCC as an additional indication. Stage 1 results for SGT-210 are due in December 2025.
Sol-Gel Technologies (NASDAQ: SLGL) has received Health Canada approval for EPSOLAY®, a treatment for inflammatory lesions of rosacea in adults. The approval, granted on August 27, 2025, comes through Sol-Gel's partnership with Searchlight Pharma, their exclusive Canadian licensee.
Under the 2023 licensing agreement, Sol-Gel is eligible to receive up to $11 million in combined milestone payments for TWYNEO and EPSOLAY, plus tiered royalties on net sales. The company expects ex-U.S. territory launches to begin in 2027-2028, with potential EBITDA contribution reaching approximately $10 million annually by 2031.
Sol-Gel is currently conducting a Phase-3 trial of SGT-610 for Gorlin syndrome and a Phase-1b trial of SGT-210 for Darier disease, as the company shifts focus toward dermatological rare diseases.
Sol-Gel Technologies (NASDAQ: SLGL) reported Q2 2025 financial results and significant corporate updates. The company announced total revenue of $17.2 million, primarily from a $16 million product sale agreement with Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. The quarter resulted in a net income of $11.6 million, or $4.17 per share.
Key developments include completion of patient enrollment for the Phase-3 trial of SGT-610 for Gorlin Syndrome, with top-line results expected in Q4 2026. The company continues its Phase-1b trial of SGT-210 for Darier disease. Sol-Gel implemented a 10-for-1 reverse share split to maintain Nasdaq listing. The company's cash position of $24.2 million is expected to extend runway into Q1 2027.
Sol-Gel Technologies (NASDAQ: SLGL) has entered into a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO. The deal will provide Sol-Gel with $16 million in two installments during 2025, extending their cash runway into Q1 2027.
The company will focus on developing SGT-610, a potential first-ever preventative treatment for basal cell carcinomas in Gorlin syndrome patients, with an estimated U.S. market potential of $400-500 million annually. The Phase III trial has achieved 80% patient enrollment, with top-line results expected in Q4 2026.
As of March 31, 2025, Sol-Gel reported $16.9 million in cash and equivalents. The company is also advancing SGT-210, a treatment for Darier disease with a market potential of $200-300 million, with 50% of patients having completed the Phase 1b trial.